June 19, 2025
(BioSpectrum Asia)
–
Singapore
,
June 19
-- Immuno Cure BioTech, a clinical-stage biotechnology startup based in
Hong Kong Science Park
, has announced its upcoming collaboration with PharmaJet(R) to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via
PharmaJet's
innovative Tropis(R) needle-free injection system in a clinical study.
Immuno Cure and
PharmaJet
held a material transfer agreement (MTA) signing ceremony at the BIO 2025
International Convention
inBoston,USAto commemorate such collaboration.
ICVAX employs Immuno Cure's patented PD-1-Enhanced DNA Vaccine technology, which aims to achieve sustained, immune-mediated HIV-1 virological control without the need ofAntiretroviral therapy (ART).
Following the successful first-in-human ICVAX Phase I clinical trial that showed exceptional safety and immunogenicity profiles, this new clinical study will explore the use of the WHO prequalified PharmaJet Tropis device for the administration of ICVAX, which allows precise intradermal delivery through its advanced needle-free technology. Tropis' global regulatory clearances and manufacturing scale reduce development risk and may improve the DNA vaccine performance and patient's clinical experience.
This study will be conducted at
Prince of Wales Hospital
in
Hong Kong
SAR, led byProfessor GraceLUI, Head of the
Division of Infectious Diseases
at the Faculty of Medicine, the
Chinese University of Hong Kong
(CUHK). This study is a collaborative effort among Immuno Cure, CUHK,and the
AIDS Institute
of theUniversity
of Hong Kong
, and is partially supported by the funding from the Public Sector Trial Scheme of the
Innovation and Technology Commission of the HKSAR Government
.Professor
Zhiwei CHEN
, Director of the
AIDS Institute
of theUniversity
of Hong Kong
, serves as the Project Coordinator for this funding. Published by HT Digital Content Services with permission from BioSpectrum Asia. For any query with respect to this article or any other content requirement, please contact Editor at contentservices@htdigital.in
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.